| http://dbpedia.org/ontology/abstract
|
Tildrakizumab, sold under the brand names … Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease. the immune system and autoimmune disease.
, Тилдракизумаб — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (март 2018 года).
|
| http://dbpedia.org/ontology/alternativeName
|
Ilumya, Ilumetri
|
| http://dbpedia.org/ontology/casNumber
|
1326244-10-3
|
| http://dbpedia.org/ontology/drugbank
|
DB14004
|
| http://dbpedia.org/ontology/fdaUniiCode
|
DEW6X41BEK
|
| http://dbpedia.org/ontology/kegg
|
D10400
|
| http://dbpedia.org/ontology/medlinePlus
|
a618026
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/tildrakizumab +
|
| http://dbpedia.org/ontology/wikiPageID
|
36964648
|
| http://dbpedia.org/ontology/wikiPageLength
|
14594
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1090573271
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Subcutaneous_injection +
, http://dbpedia.org/resource/Autoimmune_disease +
, http://dbpedia.org/resource/Interleukin_23 +
, http://dbpedia.org/resource/Schering-Plough +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Plaque_psoriasis +
, http://dbpedia.org/resource/Almirall +
, http://dbpedia.org/resource/Immune_system +
, http://dbpedia.org/resource/Sun_Pharmaceutical +
, http://dbpedia.org/resource/Interleukin-23 +
, http://dbpedia.org/resource/Phase_III_clinical_trials +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Keratinocyte +
, http://dbpedia.org/resource/Cytokine +
, http://dbpedia.org/resource/Major_adverse_cardiovascular_events +
, http://dbpedia.org/resource/Interleukin-23_receptor +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/Psoriasis_Area_and_Severity_Index +
, http://dbpedia.org/resource/Category:Merck_&_Co._brands +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/European_Commission +
|
| http://dbpedia.org/property/atcPrefix
|
L04
|
| http://dbpedia.org/property/atcSuffix
|
AC17
|
| http://dbpedia.org/property/c
|
6426
|
| http://dbpedia.org/property/casNumber
|
1326244
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/dailymedid
|
Tildrakizumab
|
| http://dbpedia.org/property/drugbank
|
DB14004
|
| http://dbpedia.org/property/h
|
9918
|
| http://dbpedia.org/property/kegg
|
D10400
|
| http://dbpedia.org/property/legalCa
|
Rx-only
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/medlineplus
|
a618026
|
| http://dbpedia.org/property/n
|
1698
|
| http://dbpedia.org/property/o
|
2000
|
| http://dbpedia.org/property/pregnancyAu
|
B1
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Subcutaneous_injection +
|
| http://dbpedia.org/property/s
|
46
|
| http://dbpedia.org/property/source
|
zu/o
|
| http://dbpedia.org/property/synonyms
|
Tildrakizumab-asmn; tildrakizumab
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/Interleukin_23 +
|
| http://dbpedia.org/property/tradename
|
Ilumya, Ilumetri
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
DEW6X41BEK
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Monoclonals_for_immune_system +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Interleukin_receptor_modulators +
, http://dbpedia.org/resource/Template:Immunosuppressants +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Portal_bar +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Merck_&_Co._brands +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Tildrakizumab?oldid=1090573271&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Tildrakizumab +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q15708331 +
, http://yago-knowledge.org/resource/Tildrakizumab +
, https://global.dbpedia.org/id/Yj33 +
, http://rdf.freebase.com/ns/m.0n4btz7 +
, http://ru.dbpedia.org/resource/%D0%A2%D0%B8%D0%BB%D0%B4%D1%80%D0%B0%D0%BA%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1 +
, http://dbpedia.org/resource/Tildrakizumab +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
|
| rdfs:comment |
Tildrakizumab, sold under the brand names … Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease. the immune system and autoimmune disease.
, Тилдракизумаб — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (март 2018 года).
|
| rdfs:label |
Tildrakizumab
, Тилдракизумаб
|
